Medtech giant Medtronic has successfully seen two patents for its sacral neuromodulation (SNM) upheld before US courts, opening the way for a lawsuit against bladder and bowel company Axonics.

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

including as a result of the Medtronic Litigation; introductions and announcements of new technologies by Axonics, any commercialization partners or Axonics’ competitors, and the timing of these ...

Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Medtronic (NYSE:MDT) has had a great run on the share market with its stock up by a significant 16% over the last three months. We, however wanted to have a closer look at its key financial ...

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the ...

Travel management highlights for medical device manufacturer Medtronic in 2023 included adding more countries to the managed program and staging a global car rental request for proposals. On the ...

Shares of Medtronic PLC MDT shed 1.38% to $87.04 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.96% to 5,695.94 and Dow ...

IRVINE, Calif., September 18, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...